About risankizum ab
Interleukin-23 (IL-23) inhibitor
Used for
- Plaque psoriasis in adults and eligible children
- Psoriatic arthritis in adults
- Crohn’s disease in adults
- Ulcerative colitis in adults
Usual adult dose
Psoriasis or psoriatic arthritis: 150 mg under the skin at weeks 0 and 4, then every 12 weeks. Crohn’s disease or ulcerative colitis: intravenous induction, then 180 or 360 mg under the skin every 8 weeks.
Usual dose in children
For plaque psoriasis in children aged 6 years and older weighing at least 40 kg: 150 mg under the skin at weeks 0 and 4, then every 12 weeks. Other pediatric uses are not established.
Common side effects
- Upper respiratory infections
- Headache
- Fatigue
- Injection-site reactions
Important warnings
- Screen for tuberculosis before treatment; treat active infection first.
- Avoid live vaccines during treatment.
- Serious infections can occur; treatment may be delayed during infection.
- Rare serious allergic reactions are possible.
Pregnancy
Human pregnancy data are limited. Use during pregnancy only when clearly needed; discuss risks with a clinician.
Breastfeeding
It is unknown whether risankizumab passes into human milk. Consider treatment benefits and breastfeeding needs with a clinician.
Interactions
- Avoid live vaccines during treatment.
- Tell clinicians about other medicines that suppress the immune system.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.